Drug Profile
Research programme: ISS-grass pollen conjugates - Dynavax
Alternative Names: ISS-grass pollen conjugates research programme - DynavaxLatest Information Update: 06 Aug 2007
Price :
$50
*
At a glance
- Originator Dynavax Technologies
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Seasonal allergic rhinitis
Most Recent Events
- 22 Mar 2005 Dynavax's ISS-grass pollen conjugates programme is no longer licensed to UCB worldwide
- 24 Oct 2003 Preclinical trials in Seasonal allergic rhinitis in USA (Injection)